First patient in trial planned for September 2019, primary outcome expected in 2021. Only patients identified as at high risk, who do not currently fulfil IWCLL treatment criteria are eligible. Patients will be randomized between observation in terms of watch&wait according to IWCLL guidelines or ...
(Blood 2008;112:5259; J Clin Oncol. 2012;30:2820) and for SLL per Lugano criteria (J Clin Oncol. 2014;32:3059).\nResults : As of 15 Apr 2020 (data cutoff), median follow-up was 18.2 mo (range, 5.0-26.3) for the 109 pts enrolled; 97 pts (89.0%) remained on treatment with ...
To be eligible, pts must be 鈮 65 yrs old, meet IW-CLL criteria for initial therapy, have adequate organ function, and ECOG PS 鈮 1. IW-CLL 2008 and CTCAE v4 criteria are used to evaluate efficacy and toxicity, with responses requiring radiographic confirmation, and evaluations after 3 ...
The study compared OS associated with the most frequent treatment sequences across the first and second lines of therapy. A total of 2354 patients met the eligibility criteria, which included having CLL/SLL, being 18 years or older at the index date...
The criteria for treatment in the second, third, and fourth line are the same as the frontline setting. Patients may relapse, or never achieve full remission with the frontline therapy and stayed away for many years. At the time the criteria are met for treatment to be reinitiated, then ...
For example, if patients met criteria where they didn't actually require a hospital admission, but they needed monitoring in a clinic, we do have regional sites around New Jersey, in Westchester, and Long Island that can be a little bit more accessible for patients. So, if [patients] do ...
An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.
aAll patients required treatment according to NCI criteria and had a life expectancy >6 months.10 bPatients with creatinine clearance <30 mL/min or inadequate liver function were excluded.9 cEach dose of oral chlorambucil is 0.5 mg/kg of body weight. Cycles 1-6: Days 1 and 15.1 ...
they’re not going to need treatment right away. Treatment is really reserved for those patients who have aggressive disease that shows symptoms. We have specific criteria in addition to the symptoms, including blood counts, drops, and so on, which we use for deciding when a patient should be...
Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586. 终点 至失败时间 (TTF) 定义 从随机化*开始直至治疗终止(由于进展、毒性或死亡等原因) 优点 常用于潜在治疗毒性与疾病进展一样严重的情况(例如异体干细胞移植) 不足 无法有效区别疗效与其他因素,例如治疗毒性 常见临床终点...